Wu et al., 2020 discovered that Luteolin was able to enhance TRAIL sensitivity in NSCLC cells by increasing the expression of death receptor 5 (DR5), the receptor of TRAIL, and increasing the dynamin-related protein 1 (Drp1) mediated mitochondrial fission through c-Jun N-terminal kinase (JNK) signaling, suggesting that combination therapy of Luteolin with TRAIL could be an effective strategy for the treatment of NSCLC [69]. Here, MAPK8 is linked to non-small cell lung carcinoma.